One of the first applications of genomic medicine into breast cancer care in HICs was the identification of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) tumor markers to target treatment. This evidence concerns the gene ERBB2 and breast cancer.